Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of CKD-501 in Renal Impairment vs Normal Function
NCT02007941Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Apr 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lobeglitazone in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration (Cmax) of Lobeglitazone and Area Under the Curve to the Last Measurable Concentration (AUCt) of Lobeglitazone. Started Apr 2014; status: completed.
02
Drugs
lobeglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02007941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02007941.